12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tesetaxel: Preliminary Phase I data

Preliminary data from 9 evaluable patients in an ongoing Phase I trial showed that 18-24 mg/m 2 oral tesetaxel resulted in 3 objective responses and 1 case of Grade 4 neutropenia. Previous Phase II trials established an MTD of...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >